Chemomab Therapeutics Ltd. has recently announced the award of new patents for its lead product, nebokitug, in China and Russia. These patents cover the use of nebokitug for treating liver diseases, including primary sclerosing cholangitis $(PSC.AU)$, with the Chinese patent providing coverage through 2038 and the Russian patent extending to 2041. This development strengthens Chemomab's intellectual property portfolio and reinforces its strategic position in addressing PSC, a debilitating disease lacking effective treatment. With these new patents, Chemomab aims to advance potential partnerships to support a Phase 3 registrational trial for nebokitug in PSC.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.